Omicron là một biến thể mới của virus Sars-cov-2, nó có khả năng lây nhiễm cao so với các biến thể khác như Alpha, Beta, Gamma và Delta. Nhiễm biến thể Omicron thường ít gây ra bệnh nghiêm trọng hơn. Dữ liệu sơ bộ cho thấy biến thể Omicron có thể gây ra bệnh nhẹ hơn, mặc dù một số người vẫn có thể mắc bệnh nặng, cần nhập viện và có thể tử vong do nhiễm biến thể này. Đến nay, Omicron được các nhà khoa học gọi là “biến thể tàng hình” với các biến thể phụ của nó và để hiểu thêm mức độ lây lan nguy hiểm của biếm thể này, Cục Thông tin KH&CN quốc gia xin giới thiệu một số bài nghiên cứu đã được xuất bản chính thức và các bài viết được chấp nhận đăng trên những cơ sở dữ liệu học thuật chính thống. Những nghiên cứu công bố trước đó trong năm 2022 được tổng hợp tại đường link cuối bài. 

PUBMED

1. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.

Ai J, Zhang H, Zhang Y, Lin K, Zhang Y, Wu J, Wan Y, Huang Y, Song J, Fu Z, Wang H, Guo J, Jiang N, Fan M, Zhou Y, Zhao Y, Zhang Q, Liu Q, Lv J, Li P, Qiu C, Zhang W.

Emerg Microbes Infect. 2022 Dec; 11(1):337-343. doi: 10.1080/22221751.2021.2022440.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788341/pdf/TEMI_11_2022440.pdf

2. Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor.

Lupala CS, Ye Y, Chen H, Su XD, Liu H.

Biochem Biophys Res Commun. 2022 Jan 29;590: 34-41. doi: 10.1016/j.bbrc.2021.12.079. Epub 2021 Dec 24.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702632/pdf/main.pdf

3. Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts.

Petersen E, Ntoumi F, Hui DS, Abubakar A, Kramer LD, Obiero C, Tambyah PA, Blumberg L, Yapi R, Al-Abri S, Pinto TCA, Yeboah-Manu D, Haider N, Asogun D, Velavan TP, Kapata N, Bates M, Ansumana R, Montaldo C, Mucheleng'anga L, Tembo J, Mwaba P, Himwaze CM, Hamid MMA, Mfinanga S, Mboera L, Raj T, Aklillu E, Veas F, Edwards S, Kaleebu P, McHugh TD, Chakaya J, Nyirenda T, Bockarie M, Nyasulu PS, Wejse C, Muyembe-Tamfum JJ, Azhar EI, Maeurer M, Nachega JB, Kock R, Ippolito G, Zumla A.

Int J Infect Dis. 2022 Jan;114: 268-272. doi: 10.1016/j.ijid.2021.11.040. Epub 2021 Dec 1.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634699/pdf/main.pdf

4. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles.

Syed AM, Ciling A, Khalid MM, Sreekumar B, Chen PY, Kumar GR, Silva I, Milbes B, Kojima N, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Spraggon L, Taha TY, Tabata T, Chen IP, Ott M, Doudna JA.

medRxiv. 2022 Jan 2:2021.12.20.21268048. doi: 10.1101/2021.12.20.21268048. Preprint.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722610/pdf/nihpp-2021.12.20.21268048v3.pdf

5. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron.

Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, Bloom NI, Goodwin B, Phillips E, Mallal S, Sidney J, Filaci G, Weiskopf D, da Silva Antunes R, Crotty S, Grifoni A, Sette A.

Cell. 2022 Mar 3;185(5):847-859.e11. doi: 10.1016/j.cell.2022.01.015. Epub 2022 Jan 24.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784649/pdf/main.pdf

6. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa.

Abdullah F, Myers J, Basu D, Tintinger G, Ueckermann V, Mathebula M, Ramlall R, Spoor S, de Villiers T, Van der Walt Z, Cloete J, Soma-Pillay P, Rheeder P, Paruk F, Engelbrecht A, Lalloo V, Myburg M, Kistan J, van Hougenhouck-Tulleken W, Boswell MT, Gray G, Welch R, Blumberg L, Jassat W.

Int J Infect Dis. 2022 Mar;116: 38-42. doi: 10.1016/j.ijid.2021.12.357. Epub 2021 Dec 28.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713416/pdf/main.pdf

7. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.

Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, Liu X, Lambe T, Crook D, Stuart DI, Mongkolsapaya J, Nguyen-Van-Tam JS, Snape MD, Screaton GR; Com-COV2 study group.

Lancet. 2022 Jan 15;399(10321):234-236. doi: 10.1016/S0140-6736(21)02844-0. Epub 2021 Dec 20.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687667/pdf/main.pdf

8. Omicron: a mysterious variant of concern.

Gowrisankar A, Priyanka TMC, Banerjee S.

Eur Phys J Plus. 2022;137(1):100. doi: 10.1140/epjp/s13360-021-02321-y. Epub 2022 Jan 10. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743750/pdf/13360_2021_Article_2321.pdf

9. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.

Kuhlmann C, Mayer CK, Claassen M, Maponga T, Burgers WA, Keeton R, Riou C, Sutherland AD, Suliman T, Shaw ML, Preiser W.

Lancet. 2022 Feb 12;399(10325):625-626. doi: 10.1016/S0140-6736(22)00090-3. Epub 2022 Jan 18.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765759/pdf/main.pdf

10. Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts - What is known so far?

Poudel S, Ishak A, Perez-Fernandez J, Garcia E, León-Figueroa DA, Romaní L, Bonilla-Aldana DK, Rodriguez-Morales AJ.

Travel Med Infect Dis. 2022 Jan-Feb;45: 102234. doi: 10.1016/j.tmaid.2021.102234. Epub 2021 Dec 8.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666662/pdf/main.pdf

11. Omicron: A highly transmissible SARS-CoV-2 variant.

Rahimi F, Talebi Bezmin Abadi A.

Gene Rep. 2022 Jun; 27:101549. doi: 10.1016/j.genrep.2022.101549. Epub 2022 Feb 10.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828449/pdf/main.pdf

12. Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2.

Han P, Li L, Liu S, Wang Q, Zhang D, Xu Z, Han P, Li X, Peng Q, Su C, Huang B, Li D, Zhang R, Tian M, Fu L, Gao Y, Zhao X, Liu K, Qi J, Gao GF, Wang P.

Cell. 2022 Feb 17;185(4):630-640.e10. doi: 10.1016/j.cell.2022.01.001. Epub 2022 Jan 6.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733278/pdf/main.pdf

13. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.

Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, André E, Leyssen P, Neyts J, Jochmans D.

Antiviral Res. 2022 Feb;198: 105252. doi: 10.1016/j.antiviral.2022.105252. Epub 2022 Jan 24.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785409/pdf/main.pdf

14. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2.

Fang Z, Peng L, Filler R, Suzuki K, McNamara A, Lin Q, Renauer PA, Yang L, Menasche B, Sanchez A, Ren P, Xiong Q, Strine M, Clark P, Lin C, Ko AI, Grubaugh ND, Wilen CB, Chen S.

bioRxiv. 2022 Feb 28:2022.02.14.480449. doi: 10.1101/2022.02.14.480449. Preprint.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863141/pdf/nihpp-2022.02.14.480449v2.pdf

15. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.

VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE Jr, Purcell LA, Kawaoka Y, Corti D, Fremont DH, Diamond MS.

Nat Med. 2022 Jan 19:1-6. doi: 10.1038/s41591-021-01678-y. Online ahead of print.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767531/pdf/41591_2021_Article_1678.pdf

WILEY

1. Transmission dynamics and mutational prevalence of the novel Severe acute respiratory syndrome coronavirus-2 Omicron Variant of Concern

Shailendra K. Saxena, Swatantra Kumar, Saniya Ansari, Janusz T. Paweska, Vimal K. Maurya, Anil K. Tripathi, Ahmed S. Abdel-Moneim

First published: 20 January 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.27611

2. An exploratory study on the propagation of SARS-CoV-2 variants: Omicron is the most predominant variant

Muthusami Rathinasamy, Saritha Kandhasamy

First published: 03 February 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.27634

3. Molecular detection of SARS-CoV-2 and differentiation of Omicron and Delta variant strains

Wai Ning Tiffany Tsui, Vaughn Hamill, Lance Noll, Nanyan Lu, Elizabeth Poulsen Porter, Donald Harbidge, Emily Cox, Claire Richardson, Mark Gray, Tesfaalem Sebhatu, Kyle Goerl …

First published: 26 February 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1111/tbed.14497

4. Omicron breakthrough infection in a kidney-transplant patient given pre-exposition casirivimab and imdevimab monoclonal antibodies

Nassim Kamar, Anna Gouin, Jacques Izopet

First published: 24 February 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1111/tid.13803

5. Coronavirus disease 2019 (COVID-19)–related smell and taste impairment with widespread diffusion of severe acute respiratory syndrome–coronavirus-2 (SARS-CoV-2) Omicron variant

Paolo Boscolo-Rizzo MD, Giancarlo Tirelli MD, Pierluigi Meloni MD, Claire Hopkins FRSC (ORLHNS), DM (Oxon), Giordano Madeddu MD, Andrea De Vito MD, Nicoletta Gardenal MD…

First published: 14 March 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1002/alr.22995

6. The puzzling mutational landscape of the SARS-2-variant Omicron

Jacques Fantini, Nouara Yahi, Philippe Colson, Henri Chahinian, Bernard La Scola, Didier Raoult

First published: 08 January 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.27577

7. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant

Dandan Tian, Yanhong Sun, Huihong Xu, Qing Ye

First published: 03 February 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.27643

8. Emerging evidence on Omicron (B.1.1.529) SARS-CoV-2 variant

Vineet Sharma, Himanshu Rai, Dev N. S. Gautam, Pradeep K. Prajapati, Rohit Sharma

First published: 26 January 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.27626

9. Convulsions in children with COVID-19 during the Omicron wave

Jonas F. Ludvigsson

First published: 31 January 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1111/apa.16276

10. Characteristics of the first 1119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November−December 2021

Linda Houhamdi, Philippe Gautret, Van Thuan Hoang, Pierre-Edouard Fournier, Philippe Colson, Didier Raoult

First published: 20 January 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.27613

11. SARS-CoV-2 Omicron variant: A next phase of the COVID-19 pandemic and a call to arms for system sciences and precision medicine

Ebrahim Mostafavi, Ankit Kumar Dubey, Laura Teodori, Seeram Ramakrishna, Ajeet Kaushik

First published: 11 February 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1002/mco2.119

12. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review

Santenna Chenchula, Padmavathi Karunakaran, Sushil Sharma, Madhavrao Chavan

First published: 04 March 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.27697

13. Acute odynophagia: A new symptom of COVID-19 during the SARS-CoV-2 Omicron variant wave in Sweden

Krzysztof Piersiala, Lara Kakabas, Anna Bruckova, Magnus Starkhammar, Lars Olaf Cardell

First published: 15 February 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.13470

14. SARS-CoV-2 Omicron variant: Immune escape and vaccine development

Danyi Ao, Tianxia Lan, Xuemei He, Jian Liu, Li Chen, Daniel T. Baptista-Hon, Kang Zhang, Xiawei Wei

First published: 16 March 2022

https://onlinelibrary.wiley.com/doi/epdf/10.1002/mco2.126

15. Challenges of the Omicron (B.1.1.529) Variant and Its Lineages: A Global Perspective

Dr. Ranjan K. Mohapatra, Dr. Venkataramana Kandi, Dr. Sarika Verma, Dr. Kuldeep Dhama

First published: 23 March 2022

https://chemistry-europe.onlinelibrary.wiley.com/doi/epdf/10.1002/cbic.202200059

SCIENCEDIRECT

1. Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals

iScience 14 March 2022 Volume 25 Issue 4 (Cover date: 15 April 2022) Article 104076

Anna-Lena Mader Leonid Tydykov David Peterhoff

https://www.sciencedirect.com/science/article/pii/S2589004222003467/pdfft?md5=847424a6930bcc8e75eee1ac86f243f9&pid=1-s2.0-S2589004222003467-main.pdf

2. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa

International Journal of Infectious Diseases 28 December 2021 Volume 116 (Cover date: March 2022) Pages 38-42

F. Abdullah J. Myers W. Jassat

https://www.sciencedirect.com/science/article/pii/S120197122101256X/pdfft?md5=412b4937d21db241d6fe11b95a1771b4&pid=1-s2.0-S120197122101256X-main.pdf

3. Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas

The American Journal of Pathology 3 February 2022 Volume 192, Issue 4 (Cover date: April 2022) Pages 642-652

Paul A. Christensen Randall J. Olsen James M. Musser

https://www.sciencedirect.com/science/article/pii/S000294402200044X/pdfft?md5=7c9c86e65338d68904c20582f182130e&pid=1-s2.0-S000294402200044X-main.pdf

4. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron

Cell 25 January 2022 Volume 185, Issue 5 (Cover date: 3 March 2022) Pages 860-871.e13

Zhen Cui Pan Liu Xiangxi Wang

https://www.sciencedirect.com/science/article/pii/S0092867422000770/pdfft?md5=0f97f2ca7c8eebecd5aa73edd6eb3258&pid=1-s2.0-S0092867422000770-main.pdf

5. Fractional order modelling of omicron SARS-CoV-2 variant containing heart attack effect using real data from the United Kingdom

Chaos, Solitons & Fractals 28 February 2022 Volume 157 (Cover date: April 2022) Article 111954

Fatma Özköse Mehmet Yavuz Rafla Habbireeh

https://www.sciencedirect.com/science/article/pii/S0960077922001643/pdfft?md5=0f0f70532e6c41a5dfc7756aef5db53e&pid=1-s2.0-S0960077922001643-main.pdf

6. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals

Cell 3 February 2022 Volume 185, Issue 6 (Cover date: 17 March 2022) Pages 1041-1051.e6

Vivek Naranbhai Anusha Nathan Gaurav D. Gaiha

https://www.sciencedirect.com/science/article/pii/S0092867422001404/pdfft?md5=ee304eb32ecf6d6e93bc84f613db1425&pid=1-s2.0-S0092867422001404-main.pdf

7. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

Cell 24 December 2021 Volume 185, Issue 3 (Cover date: 3 February 2022) Pages 447-456.e11

Markus Hoffmann Nadine Krüger Stefan Pöhlmann

https://www.sciencedirect.com/science/article/pii/S0092867421014951/pdfft?md5=2a66b8a2cc69e6cbe02d965cf0b0566b&pid=1-s2.0-S0092867421014951-main.pdf

8. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Cell6 January 2022Volume 185, Issue 3 (Cover date: 3 February 2022) Pages 457-466.e4

Wilfredo F. Garcia-Beltran Kerri J. St. Denis Alejandro B. Balazs

https://www.sciencedirect.com/science/article/pii/S0092867421014963/pdfft?md5=4e51a7f75166bfa5590194a4b26c59a7&pid=1-s2.0-S0092867421014963-main.pdf

9. Outbreak investigation of airborne transmission of Omicron (B.1.1.529) - SARS-CoV-2 variant of concern in a restaurant: Implication for enhancement of indoor air dilution

Journal of Hazardous Materials 16 February 2022 Volume 430 (Cover date: 15 May 2022) Article 128504

Vincent Chi-Chung Cheng David Christopher LungKwok-Yung Yuen

https://www.sciencedirect.com/science/article/pii/S0304389422002928/pdfft?md5=b8f89ee3c57cbb6a4f4bbec4eeabdc3a&pid=1-s2.0-S0304389422002928-main.pdf

10. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing antibodies and protection against Omicron

Cell Available online 25 March 2022 In press, journal pre-proof

Matthew Gagne Juan I. Moliva Robert A. Seder

https://www.sciencedirect.com/science/article/pii/S0092867422003889/pdfft?md5=f5dd5ebf263e4438b453efa6a2497be7&pid=1-s2.0-S0092867422003889-main.pdf

11. An evolutionary insight into Severe Acute Respiratory Syndrome Coronavirus 2 Omicron variant of concern.

Virus Research Available online 22 March 2022 In press, journal pre-proof Article 198753

Mercedes Paz Fabián Aldunate Juan Cristina

https://www.sciencedirect.com/science/article/pii/S0168170222000818/pdfft?md5=f16fff3cc5b4912a5a88ec63f67fbd3b&pid=1-s2.0-S0168170222000818-main.pdf

12. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study

The Lancet Infectious Diseases Available online 17 March 2022 In press, corrected proof

Daniel J Sheward Changil Kim Ben Murrell

https://www.sciencedirect.com/science/article/pii/S1473309922001293/pdfft?md5=fac5e8d48371e99d91a2a0e4e5b8852a&pid=1-s2.0-S1473309922001293-main.pdf

13. Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence

Microbial Pathogenesis 22 January 2022 Volume 164 (Cover date: March 2022) Article 105400

Ali Adel Dawood

https://www.sciencedirect.com/science/article/pii/S0882401022000134/pdfft?md5=b0a751218a448aa2e248ec4e24a814f2&pid=1-s2.0-S0882401022000134-main.pdf

14. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants

Cell Available online 18 March 2022 In press, journal pre-proof

Venice Servellita Abdullah M. Syed Charles Y. Chiu

https://www.sciencedirect.com/science/article/pii/S0092867422003294/pdfft?md5=2915156dcfcb0aabd3f2738afbe44399&pid=1-s2.0-S0092867422003294-main.pdf

15. Is Omicron the last SARS-CoV-2 Variant of Concern?

Archives of Medical Research Available online 19 January 2022 In press, corrected proof

Farid Rahimi Amin Talebi Bezmin Abadi

https://www.sciencedirect.com/science/article/pii/S0188440922000017/pdfft?md5=134be6d9459b086e934d723ee62860a4&pid=1-s2.0-S0188440922000017-main.pdf

Các công bố về COVID-19 trước thời gian trên:

Cập nhật các công bố về COVID-19 từ ngày 18/3 đến ngày 25/3/2022

https://vista.gov.vn/news/cac-linh-vuc-khoa-hoc-va-cong-nghe/vac-xin-sars-cov-2-va-nhung-thong-tin-lien-quan-cap-nhat-den-25-3-2022-4800.html

Cập nhật các công bố về COVID-19 từ ngày 11/3 đến ngày 18/3/2022

https://vista.gov.vn/news/cac-linh-vuc-khoa-hoc-va-cong-nghe/nhung-thong-tin-ve-sars-cov-2-hien-nay-ngay-11-3-18-3-2022-4778.html

Cập nhật các công bố về COVID-19 từ ngày 4/3 đến ngày 11/3/2022

https://vista.gov.vn/news/cac-linh-vuc-khoa-hoc-va-cong-nghe/bien-the-cua-sars-cov-2-ngay-4-11-3-2022-4753.html

Cập nhật các công bố về COVID-19 từ ngày 25/3 đến ngày 4/3/2022

https://vista.gov.vn/news/cac-linh-vuc-khoa-hoc-va-cong-nghe/nhung-nghien-cuu-phan-tich-ve-covid-19-ngay-25-2-4-3-2022-4729.html

Cập nhật các công bố về COVID-19 từ ngày 18/2 đến ngày 25/2/2022

https://vista.gov.vn/news/cac-linh-vuc-khoa-hoc-va-cong-nghe/vac-xin-covid-19-va-nhung-xu-huong-nghien-cuu-ngay-18-2-25-2-2022-4707.html

Cập nhật các công bố về COVID-19 từ ngày 11/2 đến ngày 18/2/2022

https://vista.gov.vn/news/cac-linh-vuc-khoa-hoc-va-cong-nghe/covid-19-va-nhung-tac-dong-doi-voi-doi-song-ngay-11-18-2-2022-4685.html

Cập nhật các công bố về COVID-19 từ ngày 4/2 đến ngày 11/2/2022

https://vista.gov.vn/news/cac-linh-vuc-khoa-hoc-va-cong-nghe/nghien-cuu-moi-ve-covid-19-tu-ngay-4-2-den-ngay-11-2-2022-4664.html

Cập nhật các công bố về COVID-19 từ ngày 21/1 đến ngày 28/1/2022

https://vista.gov.vn/news/cac-linh-vuc-khoa-hoc-va-cong-nghe/nghien-cuu-moi-ve-vaccine-covid-19-tu-ngay-21-01-den-ngay-28-01-2022-4639.html

Cập nhật các công bố về COVID-19 từ ngày 14/1 đến ngày 21/1/2022

https://vista.gov.vn/news/cac-linh-vuc-khoa-hoc-va-cong-nghe/nghien-cuu-moi-ve-vaccine-covid-19-tu-ngay-14-1-den-ngay-21-1-2022-4618.html

Cập nhật các công bố về COVID-19 từ ngày 7/1 đến ngày 14/1/2022

https://vista.gov.vn/news/cac-linh-vuc-khoa-hoc-va-cong-nghe/nghien-cuu-moi-ve-vaccine-covid-19-tu-ngay-7-1-den-ngay-14-1-2022-4601.html

Cập nhật các công bố về COVID-19 từ ngày 1/1 đến ngày 7/1/2022

https://vista.gov.vn/news/cac-linh-vuc-khoa-hoc-va-cong-nghe/nghien-cuu-moi-ve-vaccine-covid-19-tu-ngay-3-1-den-ngay-7-1-2022-4584.html

Nguồn: Cục Thông tin khoa học và công nghệ quốc gia, 1/4/2022